Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $6.00 | Buy | Craig Hallum |
| 10/7/2024 | $4.00 | Neutral | UBS |
| 2/25/2022 | $3.00 → $2.50 | Market Perform | SVB Leerink |
| 2/2/2022 | $7.00 → $3.00 | Underperform → Market Perform | Cowen & Co. |
| 2/2/2022 | $6.00 | Buy | Canaccord Genuity |
| 1/19/2022 | $3.00 | Market Perform | SVB Leerink |
| 1/10/2022 | $9.00 → $3.50 | Neutral | Citigroup |
| 1/7/2022 | $9.00 → $3.50 | Neutral → Underperform | Credit Suisse |
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00
UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00
SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
WILMINGTON, Del., March 03, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced it has partnered with Google Cloud to integrate Vertex AI Search into its flagship technology, Counterpart Assistant. This innovation gives providers on Counterpart Assistant a generative AI (gen AI) search experience across the breadth of a patient's digital health record to provide contextualized insights, and to make it easier to deliver value-based care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). Physicians struggle to access and synthesize the vast amounts of data within
Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpointInsurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointAdjusted EBITDA profitability between $45 million and $70 millionAdjusted Net income between
WILMINGTON, Del., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), today announced its participation in the following investor conferences: CFO, Peter Kuipers, will participate in the 2025 Jefferies Value-Based Healthcare Summit on Monday, March 10, 2025.CFO, Peter Kuipers, will present at the 2025 Leerink Global Healthcare Conference on Tuesday, March 11, 2025, at 8:00 a.m. Eastern Time. A live webcast and replay of the presentation and Q&A session will be accessible from Clover Health's investor relations website at https://investors.cloverhealth.com/. About Clover Health:Clover Health (NASDAQ:CLOV) is a physician enablement technology
Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpointInsurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointAdjusted EBITDA profitability between $45 million and $70 millionAdjusted Net income between
WILMINGTON, Del., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), today announced that it will report fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on February 27, 2025, to discuss Clover Health's fourth quarter and full year 2024 business and financial results. Fourth Quarter and Full Year 2024 Conference Call and Webcast Details: What: Clover Health's Fourth Quarter and Full Year 2024 Earnings Conference CallWhen: Thursday, February 27, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via tele
Delivers 9% Total Revenue growth year-to-date compared to prior year period Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by $117.4 million year-over-year and year-to-date Adjusted EBITDA by $87.2 million year-over-year Increases Full-Year 2024 guidance midpoint to target updated range of Adjusted EBITDA profitability of $55 million - $65 million, strongly positioning the Company to invest in membership growth opportunity for 2025 FRANKLIN, Tenn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today reported financial results for the third quarter 2024. Management will host a co
144 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
S-8 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
144 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart's clinical strategy and product roadmap for Counterpart Assistant, the company's proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). David Tsay is a distinguished physician executive with deep expertise and over two decades of ex
FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health" or "Clover"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Mr. Brand will oversee core MA operations and drive performance improvements, with a focus on improving healthcare delivery in New Jersey by leveraging operational efficiencies and technological innovation. Mr. Brand brings nearly 20 years of healthcare leadership experience, having held prominent positions in healthcare operation
FRANKLIN, Tenn., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced it has appointed Thomas L. Tran to the Company's Board of Directors (the "Board"), and as a member of the Audit Committee. "Tom Tran's appointment to our Board marks a significant enhancement to our strategic financial planning and execution capabilities. With his impressive track record at the helm of finance at public managed care organizations, Tom is uniquely qualified to help guide Clover Health as we advance o
The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso